+

WO2008066641A3 - Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors - Google Patents

Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors Download PDF

Info

Publication number
WO2008066641A3
WO2008066641A3 PCT/US2007/022923 US2007022923W WO2008066641A3 WO 2008066641 A3 WO2008066641 A3 WO 2008066641A3 US 2007022923 W US2007022923 W US 2007022923W WO 2008066641 A3 WO2008066641 A3 WO 2008066641A3
Authority
WO
WIPO (PCT)
Prior art keywords
mitf
treating
inhibitors
methods
associated diseases
Prior art date
Application number
PCT/US2007/022923
Other languages
French (fr)
Other versions
WO2008066641A2 (en
Inventor
Gerhard Hannig
Sylvie Bernier
Original Assignee
Praecis Pharm Inc
Gerhard Hannig
Sylvie Bernier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharm Inc, Gerhard Hannig, Sylvie Bernier filed Critical Praecis Pharm Inc
Publication of WO2008066641A2 publication Critical patent/WO2008066641A2/en
Publication of WO2008066641A3 publication Critical patent/WO2008066641A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The instant invention provides methods and compositions for treating a subject suffering from an MITF associated disease, such as Microphthalmia, Waardenburg syndrome type 2a, Tietz syndrome, digenic ocular albinism, Sensorineural deafness, albinism, and osteoporosis. The invention also provides methods and compositions for modulating a function of MITF, inducing melanogenesis in a melanocyte or a melanoma cell, and sensitizing a melanoma cell to a chemotherapeutic agent.
PCT/US2007/022923 2006-11-06 2007-10-30 Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors WO2008066641A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85706306P 2006-11-06 2006-11-06
US60/857,063 2006-11-06

Publications (2)

Publication Number Publication Date
WO2008066641A2 WO2008066641A2 (en) 2008-06-05
WO2008066641A3 true WO2008066641A3 (en) 2008-08-21

Family

ID=39468428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022923 WO2008066641A2 (en) 2006-11-06 2007-10-30 Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors

Country Status (1)

Country Link
WO (1) WO2008066641A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042295A2 (en) * 2000-11-01 2002-05-30 Praecis Pharmaceuticals Inc. Peptides as met-ap2 inhibitors
WO2003092608A2 (en) * 2002-05-02 2003-11-13 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
WO2005066197A2 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
WO2006010498A2 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2007124005A2 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042295A2 (en) * 2000-11-01 2002-05-30 Praecis Pharmaceuticals Inc. Peptides as met-ap2 inhibitors
WO2003092608A2 (en) * 2002-05-02 2003-11-13 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
WO2005066197A2 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
WO2006010498A2 (en) * 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2007124005A2 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANNIG GERHARD ET AL: "Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 28, no. 4, April 2006 (2006-04-01), pages 955 - 963, XP009101250, ISSN: 1019-6439 *
KOYAMA HIDENORI ET AL: "The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I: Possible involvement of cyclin-dependent kinase 2", CIRCULATION RESEARCH, vol. 79, no. 4, 1996, pages 757 - 764, XP009101237, ISSN: 0009-7330 *
OWA T ET AL: "Cell cycle regulation in the G1 phase: A promising target for the development of new chemotherapeutic anticancer agents", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, no. 12, 1 January 2001 (2001-01-01), pages 1487 - 1503, XP009100820, ISSN: 0929-8673 *

Also Published As

Publication number Publication date
WO2008066641A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
NO20084368L (en) Stable emulsion formulations
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
DK2579900T3 (en) VECTORS AND SEQUENCES FOR THE TREATMENT OF DISEASES
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007100617A3 (en) Imidazole-based compounds, compositions comprising them and methods of their use
BRPI0718927A2 (en) IMMUNIZATION METHOD AGAINST DENGUE'S FOUR SEROTIPES.
TW200626132A (en) Topical nepafenac formulations
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
EA201171339A1 (en) THE WAY TO REDUCE THE INTRA-GL PRESSURE IN PEOPLE
WO2007109523A3 (en) Stabilized ophthalmic compositions comprising oxidatively unstable components
WO2007144521A3 (en) Cosmetic composition for topical use comprising wasabi
WO2007123740A3 (en) Pharmaceutical compositions for promoting wound healing
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2009032843A3 (en) Deuterated ethambutols and their use
WO2006131401A3 (en) Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
TW200704409A (en) Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
ES2325291A1 (en) Use of a silybum marianum extract
WO2008066641A3 (en) Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors
NO20064834L (en) Prolonged release of compositions comprising torasmid and a matrix forming polymer.
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
WO2008125771A3 (en) Cosmetic use of a debaryomyces hansenii extract

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870827

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07870827

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载